Global cell therapy up to 1483 kinds of Chinese research and development tests follow the United States

TextsIn the latest day, Nature Reviews Drug Discovery 2020 report shows that the field of cell immunotherapy continues to expand, with 1,483 active therapies in the global cancer cell therapy pipeline as of March, an increase of 472 compared to 2019, with CAR-T therapy increasing by 290, compared with 164 in 2019This year, the number of new T-cell methods and other cell therapies increased to 49 and 56, respectivelyThe report shows that CD19 is the main target of cell immunotherapy in blood cancer indications, however, the number of active drugs being studied for target B cell maturation antigens (BCMA) or CD22 has almost doubled since 2019, and both BCMA and CD22 are antigens expressed on the surface of B cellsIn the direction of solid tumors, undisclosed tumor-related antigens (TAA) were the main targets, in addition, cell therapy targeting GPC3 and prostate-specific membrane antigens (PSMA) increased the mostAccording to the report, the United States and China dominate cancer cell treatment research and development pipelines, with 600 in the U.Sand 508 in China after the U.Sby March 2020, but China is doing more cell therapy trials than the U.S., with 871 in China and 718 in the U.SIn addition, most cell therapies in the U.Sare developed by pharmaceutical companies, and in the past cell therapy in China has been developed by academic institutions, but for the first time since last year, chinese pharmaceutical companies have developed more cell therapies than those developed by academic institutions, with clinical studies increasing from 69 to 202 in a year, a threefold increase, but it remains to be seen whether these studies will reach the end of the studyIt is worth mentioning that China's Phase 1 and Phase 2 clinically developed cancer cell therapy programs are also growing at a rate of about 50% per year, at a rate synchronized with that of the United StatesIt is worth noting that China continues to develop new cell therapies and transition from academia to the pharmaceutical industry, which may require further improvements in the rigour of researchOver the past year, China has seen an increase in advance in preclinical research and has become one of the leaders in cancer cell therapy trialsHowever, due to the COVID-19 pandemic, this momentum is likely to be affected by the widespread destruction of global clinical trials in all therapeutic areasHowever, globally, the number of research on cell therapy for blood and solid tumors is increasing in various countries, and the largest active drugs being developed on behalf of immunothology will gradually increase, and cell therapy will be a therapeutic research that will be of concern for a long time to come.